Vertex Pharmaceuticals updated clinical data from their investigational stem cell therapy for type 1 diabetes, revealing that 10 of 12 patients discontinued insulin use a year post-infusion. The off-the-shelf therapy, designed to replace damaged islet cells with lab-grown insulin-producing cells, demonstrated sustained efficacy and safety, with none experiencing severe hypoglycemia after 3 months. These results, presented at ADA 2025 and published in the New England Journal of Medicine, signal promising advances in cell replacement strategies for diabetes management, expanding therapeutic options beyond exogenous insulin dependency.